We develop a model for the host-virus dynamics of HTLV-I with target cell latency.

A balance between proviral activation and latency aids viral persistence.

Immune efficiency depends on rate of lysis and not on abundance of effector cells.

Proviral activation may distinguish clinical status independent of proviral load.

We hypothesise that crossing an activation threshold could increase risk of disease.